IDiyas

For the Inventor, By the Inventor

Osaka, Japan

Masashi Kato

USPTO Granted Patents = 13 


Average Co-Inventor Count = 3.1

ph-index = 5

Forward Citations = 75(Granted Patents)


Location History:

  • Mishima-gun, JP (2008 - 2011)
  • Osaka, JP (1998 - 2019)

Company Filing History:

goldMedal12 out of 574 
 
Ono Pharmaceutical Co., Ltd.
 patents
silverMedal1 out of 22 
 
Ono Pharmaceuticals Co., Ltd.
 patents

Years Active: 1998-2019

Loading Chart...
Loading Chart...
13 patents (USPTO):Explore Patents
1. 10519105 - KCNQ2-5 channel activator (2019-12-31),
2. 8952158 - Tricyclic compound and use thereof (2015-02-10),
3. 8476293 - Tricyclic compound and use thereof (2013-07-02),
4. 7964726 - Tricyclic compound and use thereof (2011-06-21),
5. 7872133 - Tricyclic heterocycle compound (2011-01-18),
6. 7427634 - Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them (2008-09-23),
7. 7368444 - N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient (2008-05-06),
8. 7351721 - Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them (2008-04-01),
9. 7166590 - Amino acid derivatives (2007-01-23),
10. 6903119 - Amino acid derivatives and drugs containing the same as the active ingredient (2005-06-07),
11. 6605608 - Amino acid derivatives and drugs containing the same as the active ingredient (2003-08-12),
12. 5998410 - Sulfonamide derivatives (1999-12-07),
13. 5795890 - Sulfonamide derivatives (1998-08-18),

Title: Masashi Kato: Innovator in Pharmaceutical Compounds

Introduction

Masashi Kato is a prominent inventor based in Osaka, Japan, known for his significant contributions to the field of pharmaceuticals. With a total of 13 patents to his name, Kato has developed innovative compounds that address various medical conditions.

Latest Patents

One of Kato's latest patents is the KCNQ2-5 channel activator. This invention aims to provide a novel compound that exhibits a strong opening action with respect to KCNQ2-5 channels. The compound, represented by a specific general formula, is designed to be useful as a prophylactic and/or therapeutic agent for diseases related to KCNQ2-5 channels, such as dysuria and overactive bladder. Another significant patent is for a tricyclic compound, which has an anti-stress action. This compound is particularly useful for preventing and treating diseases caused by stress, especially those affecting the digestive system, and demonstrates superior oral absorption.

Career Highlights

Kato has worked with notable companies in the pharmaceutical industry, including Ono Pharmaceutical Co., Ltd. and Ono Pharmaceuticals Co., Ltd. His work has been instrumental in advancing the development of therapeutic agents that improve patient outcomes.

Collaborations

Throughout his career, Kato has collaborated with esteemed colleagues such as Takuya Seko and Kazuyuki Ohmoto. These partnerships have contributed to the successful development of his innovative compounds.

Conclusion

Masashi Kato's contributions to pharmaceutical innovations highlight his role as a leading inventor in the field. His patents reflect a commitment to addressing critical health issues through novel compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…